Effects of Angiotensin-Converting Enzyme Inhibition on Circulating Endothelial Progenitor Cells in Patients with Acute Ischemic Stroke

Table 3

Clinical characteristics of groups Ia and Ib.

Clinical feature	Group Ia ()	Group Ib ()	value
Qualitative parameters	(%)	(%)	value
Male gender	14 (42.4)	6 (60.0)	0.3289
Severe clinical status
NIH ≤ 7	14 (42.4)	3 (30.0)	0.4815
NIH 8–17	9 (27.3)	4 (40.0)	0.4427
NIH > 18	10 (30.3)	3 (30.0)	0.9854
Neurological status improvement:
No improvement	11 (33.3)	5 (50.0)	0.9086
Improvement < 50%	10 (30.3)	3 (30.0)	0.4665
Improvement > 50% or complete recovery	12 (36.4)	2 (20.0)	0.0857
Death	2 (6.5)	1 (10.0)	0.7079
Stroke subtypes
Large artery atherosclerosis	18 (54.5)	6 (60.0)	0.5266
Cardioembolic	3 (9.1)	1 (10.0)	0.6684
Small vessel disease	2 (6.1)	1 (10.0)	0.5579
Other determined etiologies	1 (3.0)	0 (0)	0.4963
Undetermined etiology	9 (27.3)	2 (20.0)
Hypertension	33 (100)	10 (100)	1.0000
Dyslipidemia	15 (45.5)	2 (20.0)	0.1492
Diabetes mellitus	13 (39.4)	2 (20.0)	0.2596
Current smoker	4 (12.1)	4 (40.0)	0.0547
Excessive alcohol intake	6 (18.1)	2 (20.0)	0.8970
Obesity	9 (27.3)	2 (20.0)	0.7465
Overweight	15 (45.5)	5 (50.0)	0.8989
Coronary heart disease	21 (63.6)	4 (40.0)	0.1844
Atrial fibrillation	13 (39.4)	3 (30.0)	0.5903
ACE inhibitors	33 (100)	0 (0)	—
Aspirin	17 (51.5)	1 (10.0)	0.0197
Enoxaparin	2 (6.1)	0 (0)	0.4253
Thrombolitic therapy	3 (9.1)	3 (30.0)	0.1270
Quantitative parameters	Mean ± SD	Mean ± SD	value
Age	76.2 ± 9.43	71.6 ± 16.06	0.4376
Plasma hsCRP (mg/L)	9.6 ± 20.63	3.4 ± 4.64	0.0223
Plasma fibrinogen (mg/dL)	393.8 ± 83.98	330.6 ± 101.69	0.0478
White blood cells (WBC) (G/L)	9.6 ± 9.81	9.2 ± 7.63	0.8213
Plasma total homocysteine (μmol/L)	14.8 ± 9.77	11.9 ± 3.39	0.7848
Lipid profile (mg/dl)
Total cholesterol	178.7 ± 45.78	176.6 ± 40.52	0.8181
LDL cholesterol	111.1 ± 40.16	110.9 ± 38.65	0.9313
HDL cholesterol	45.5 ± 14.26	45.4 ± 12.44	0.8518
Triglycerides	109.4 ± 36.3	126.2 ± 51.05	0.3652

Chi-squared test. Mann–Whitney U test.